Showing 1 - 20 results of 30,470 for search '(( via mapk decrease ) OR ((( _ ((teer decrease) OR (a decrease)) ) OR ( _ largest decrease ))))', query time: 0.48s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. …”
  7. 7
  8. 8
  9. 9

    Table 2_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.docx by Bo Chen (32294)

    Published 2025
    “…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
  10. 10

    Image 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.pdf by Bo Chen (32294)

    Published 2025
    “…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
  11. 11

    Table 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.docx by Bo Chen (32294)

    Published 2025
    “…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
  12. 12

    Data Sheet 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.zip by Bo Chen (32294)

    Published 2025
    “…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20